Form 8-K ACADIA PHARMACEUTICALS For: May 08
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Acadia Pharmaceuticals (ACAD) PT Lowered to $22 at BofA Securities
May 10, 2024 5:24 AM EDTBofA Securities analyst Tazeen Ahmad lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $22.00 (from $26.00) while maintaining a Neutral rating.
The analyst comments "ACAD reported 1Q24 Daybue revenues of $75.9mn slightly missing their 1Q guidance of $76-82mn. Mgmt attributed the 1Q... More
